Rifater

Rifampicin, the only commercially available ansamacroHde, is manufactured by MerreU Dow under the tradename Rifadin, and by CIBA under the trade name Rimactane. Rifampicin is also suppHed in combination with isoniazid or pyrazinamide [98-96-4]. The rifampicin—isoniazid combination is known as Rifamate (MerreU Dow), Rifinah (MerreU Dow), and Rimactazid (CIBA) the rifampicin—pyrazinamide as Rifater (MerreU Dow). Several other rifamycin derivatives including rifabutin and rifapentine are undergoing clinical studies. 

L Arguenon)-comb. Rifater (Marion Merrell)-comb. 

Pyrazinamid "Lederle" GB Rifater (Hoechst)-comb. Merrell)-comb. 

Rifater (GriinenthaO-comb. Rifinah (Griinenthal)-comb. F Rifadine (Marion Merrell... 

GB Rifadin (Hoechst 1969) Rifater (Hoechst)-comb. with isoniazid Rifinah (Hoechsl)-comb. with isoniazid Rimactane (Ciba 1969) Rimactazid (Ciba)-comb. with isoniazid I Rifadin (Lepetit)... 

Walser TC, Rifat S, Ma X, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006 66 7701-7707. 

Rifater Tuberculostatic Tab Rifampin 120 mg, isoniazid 50 mg, pyrazinamide 6 tabs once daily. Reduce dose to 5 tabs if <54 300 mg kg, and to 4 tabs if <441 ... 

Rx with rifampin (Rifamate) with rifampin, pyrazinamide (Rifater)... 

Flint AJ, Rifat SL. Two-year outcome of psychotic depression in late life. Am J Psychiatry 1998 155 178-183. 

Flint AJ, Rifat SL. The treatment of psychotic depression in later life a comparison of pharmacotherapy and ECT. Int J Gerlatr Psychiatry 1998 13 23-28. 

To document these visual delights Claude Rifat, who was trained as a scientist in Geneva after his idyllic childhood in Saudi Arabia, made extensive sketches and notes, as part of his own effort to develop a theory of mind that could be related to basic science. But because he was not an artist, he asked Gilles Roth of the Museum of Natural History in Geneva, Switzerland to redraw them in the form shown here. 

Like many of his contemporaries, Claude Rifat was drawn to experimentation with psychoactive drugs, but he soon learned that he could accomplish the effects he sought without them. Through his contact with the French psychobiologist Henri Laborit, he was inspired to elaborate models of these transformations that involve the natural neuromodulator serotonin, just as I will do in chapter 7. Claude Rifat s life has led him back to the east, but now it is the extreme orient that he calls home. There he has felt freer to pursue his self-observation based scientific inquiries and develop his personal, social, and ecological ideals. 

Tramer, M. R., Schneider, J., Marti, R.-A., Rifat, K. Role of magnesium sulfate in postoperative analgesia, Anaesthesiology 1996, 84, 340-347. 

Subtle neurological effects have also been observed in workers chronically exposed to aluminum dust or fumes. These effects include impaired performance on neurobehavioral tests, increased reporting of subjective neurological symptoms, and altered EEGs (Bast-Peetersen et al. 1994 Hanninen et al. 1994 Hosovski et al. 1990 Rifat et al. 1990 Sjogren et al. 1996 White et al. 1992). Poor characterization of aluminum exposure precludes using these studies to develop an inhalation MRL for aluminum. 

Comparative Toxicokinetics. The animal data indicate that the nervous system is a sensitive target of toxicity for aluminum following oral exposure, as summarized in the Data Needs sections on Neurotoxicity. Although the interpretation of the human data is limited by poor exposure characterization, the occupational exposure studies suggest that neurotoxicity is also a sensitive end point following inhalation exposure (Hanninen et al. 1974 Hosovski et al. 1990 Rifat et al. 1990 Sim et al. 1997 Sjogren et al. 1996 White et al. 1992). The toxicokinetic properties of aluminum have been extensively studied in human and animals. The results of these studies suggest that the absorption, distribution, and excretion properties of aluminum are similar across species. 

Rifat SL. 1993. Alzheimer s disease and environmental aluminum. Age Ageing 22 476-477. 

Rifat SL, Eastwood MR, Crapper-McLachlan DR, et al. 1990. Effect of exposure of miners to aluminum powder. Lancet 336 1162-1165. 

Rifater (Marion Mcrrcll)- Nicazide (IF1) Tuberon (Shionogi)... 

---